Work

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Year: 2016

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v128.22.998.998

Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L Bartlett, Tanya Siddiqi, Caron A. Jacobson, Jason R. Westin, Julio C. Chavez, Armin Ghobadi, Alex F Herrera, Ann S. LaCasce, Adrian Bot, John M. Rossi, Yizhou Jiang, Jeff S. Aycock, Meg Elias, Jeff Wiezorek, William Y. Go

Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, City Of Hope National Medical Center, Dana-Farber Cancer Institute, Kite Pharma (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596837024

FWCI: 2.48

Cites:

Cited by: 27

Related to: 10